GastroPanel® is a first line diagnostic test for dyspeptic patients. It is a non-invasive blood test, risk free and user friendly laboratory test.
GastroPanel gives information on the structure and function of the stomach mucosa, and of the risks caused by a possible abnormal mucosa. Based on the GastroPanel results, it is possible to get information to support the diagnosis of:
Healthy stomach mucosa
Functional and organic dyspepsia (when GastroPanel results indicate a healthy stomach mucosa, the cause of stomach problems is often functional dyspepsia or a disease outside the stomach).
Atrophic gastritis (damaged stomach mucosa that is severly dysfunctional) and likelihoods of the conditions specifically in the corpus and antrum areas of the stomach (normal, gastritis or atrophic gastritis).
Biohit Active B12 (holotranscoblamin) ELISA – an accurate test for measuring the levels of active vitamin B12
The traditional method of diagnosing vitamin B12 deficiency has been to measure the concentration of total vitamin-B12 in the serum. The total vitamin B12 concentration essentially reflects vitamin-B12 which is bound to its two carrier proteins forming, holohaptocorrin (holoHC) and holotranscobalamin(holoTC). Whilst holoHC accounts for 70 % – 80 % of the vitamin B12 in serum, only holoTC (active vitamin B12) can be used by human cells. Measurement of total vitamin B12 can hence give erroneous results because it measures the vitamin B12 which is in circulation but does not indicate the active vitamin B12 that is available to the cells of the body.
Biohit Active B12 test provides a solution to this diagnostic paradox: this test directly measures (holoTC) – the biochemically active form of vitamin B12 – from the human serum. This test is well suited for the screening of patients with a suspected vitamin B12 deficiency. Biohit Active B12 test can also be used for confirming the vitamin B12 status in the large number of patients who get an inconclusive result from total vitamin B12 tests.
Measures the concentration of active vitamin B12 (holotranscobalamin) available to the cells
Proven ELISA technology, support for both automated and manual analysis methods
Unlike total B12 kits, no issues with Intrinsic Factor Blocking Antibody (IFBA) interferences
Numerous clinical studies proving the performance of Active B12 over total B12
The best indicator of vitamin D status is the serum concentration of 25OH vitamin D. For a correct diagnosis of vitamin D deficiency, the assay must recognize two vitamins important in the human body, vitamin D2 and D3.
The BIOHIT Total 25OH vitamin D ELISA kit is a quantitative immunoenzymatic assay. While detecting both 25OH vitamin D2 and D3, the kit provides clinically relevant information on the vitamin D status. Reliability of the results is ensured by validation against the ID-LC/ MS-MS Reference Measurement Procedure (Ghent method) as approved by the Vitamin D Standardization Program (VDSP) with R>0.97.
Vitamin D has multiple roles in the human body. In addition to its well established role in the regulation of calcium absorption and promoting bone growth, it is recognized for other health benefits including reducing risk of diseases such as type 1 diabetes and common cancers.
Two major forms of vitamin D are important in the human body, vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D3 is the form synthesized in the skin in response to sunlight UVB exposure yet can also be obtained from animal based foods. Vitamin D2, on the other hand, is the form synthesized by plants and is obtained from plant derived foodstuff. Both are metabolized in the liver to their respective 25OH vitamin D3 and D2 forms which are in turn converted to their active form in the kidneys.
The best indicator of vitamin D status is the serum concentration of 25OH vitamin D. For a correct diagnosis of vitamin D deficiency, insufficiency or intoxication, the assay must recognize both the D2 and D3 forms. As both forms have clinical relevance, the total concentration provides the information that can be acted upon.
Biohit Oyj is a globally operating Finnish biotechnology company. We promote wellbeing and quality of life across the globe by developing, manufacturing and marketing acetaldehyde binding products (for smoking cessation and stomach health) and diagnostic tests for researchers working in clinical and industrial laboratories to make early diagnosis possible. Biohits mission is “Innovating for Health”. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. Read more: www.biohithealthcare.com